{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:42:28Z","timestamp":1789926148562,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bmc.2017.09.011","type":"journal-article","created":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T20:30:24Z","timestamp":1504989024000},"page":"2859-2862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Therapeutic peptides for CNS indications: Progress and challenges"],"prefix":"10.1016","volume":"26","author":[{"given":"Bruce H.","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2017.09.011_b0005","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.1072873","article-title":"Treatment of ischemic brain damage by perturbing NMDA Receptor-PSD-95 protein interactions","volume":"298","author":"Aarts","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.09.011_b9005","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1091\/mbc.E15-12-0857","article-title":"The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5\/p35 activity from inhibition by TFP5, a peptide derived from p35","volume":"27","author":"Amin","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.bmc.2017.09.011_b0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing towards the dream","volume":"3","author":"Arkins","year":"2004","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.bmc.2017.09.011_b0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd.2016.237","article-title":"Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective","volume":"15","author":"Butlen-Ducuing","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2017.09.011_b0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nature10841","article-title":"Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain","volume":"483","author":"Cook","year":"2012","journal-title":"Nature"},{"issue":"154","key":"10.1016\/j.bmc.2017.09.011_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003824","article-title":"A translational paradigm for the preclinical evaluation of stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates","volume":"4","author":"Cook","year":"2012","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.bmc.2017.09.011_b0030","doi-asserted-by":"crossref","first-page":"16435","DOI":"10.3390\/molecules200916435","article-title":"Small molecule targeting of protein-protein interactions through allosteric modulation of dynamics","volume":"20","author":"Cossins","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2017.09.011_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/bi400377p","article-title":"Development and mechanism of \u03b3-secretase modulators for Alzheimer\u2019s disease","volume":"52","author":"Crump","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2017.09.011_b0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alz Res Ther"},{"key":"10.1016\/j.bmc.2017.09.011_b0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-pharmtox-010814-124309","article-title":"Learning by failing: ideas and concepts to tackle \u03b3-secretases in Alzheimer\u2019s disease and beyond","volume":"55","author":"De Strooper","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2017.09.011_b0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-2006-102-312","article-title":"Presenilin structure in mechanisms leading to Alzheimer\u2019s disease","volume":"10","author":"Dewji","year":"2006","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bmc.2017.09.011_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122451","article-title":"Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce b-amyloid in Alzheimer\u2019s disease","author":"Dewji","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2017.09.011_b0060","unstructured":"Dewji NN. Preclinical studies on P8, a novel Alzheimer\u2019s disease-modifying peptide drug candidate. AsiaTIDES: Oligonucleotide and Peptide Therapeutic Conference. Kyoto, Japan; 2017."},{"key":"10.1016\/j.bmc.2017.09.011_b0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global burden of stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.bmc.2017.09.011_b0070","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"\u03b3-secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.bmc.2017.09.011_b0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm0109-20","article-title":"Gamma-secretase inhibitors: notch so bad","volume":"15","author":"Grosveld","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2017.09.011_b0080","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1474-4422(12)70225-9","article-title":"Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomized, double-blind, placebo-controlled trial","volume":"11","author":"Hill","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2017.09.011_b0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cn2000469","article-title":"ACS chemical neuroscience molecule spotlight on ELND006: another \u03b3-secretase inhibitor fails in the clinic","volume":"2","author":"Hopkins","year":"2011","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2017.09.011_b0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10571-009-9410-6","article-title":"Targeting Cdk5 activity in neuronal degeneration and regeneration","volume":"29","author":"Kanungo","year":"2009","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bmc.2017.09.011_b0095","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","article-title":"Future directions for peptide therapeutics development","volume":"18","author":"Kaspar","year":"2013","journal-title":"Drug Disc Today"},{"key":"10.1016\/j.bmc.2017.09.011_b0100","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for central nervous system disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.bmc.2017.09.011_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2017.09.011_b0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drudis.2016.10.010","article-title":"Amyloid beta modulators and neuroprotection in Alzheimer\u2019s disease: a critical appraisal","volume":"22","author":"Kuruva","year":"2017","journal-title":"Drug Disc Today"},{"key":"10.1016\/j.bmc.2017.09.011_b0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","article-title":"Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults","volume":"1","author":"Lipton","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.bmc.2017.09.011_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/alzrt220","article-title":"Treating Alzheimer\u2019s disease with monoclonal antibodies: current status and outlook for the future","volume":"5","author":"Prins","year":"2013","journal-title":"Alz Res Ther"},{"key":"10.1016\/j.bmc.2017.09.011_b0135","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1242\/jcs.147553","article-title":"Cdk5 activity in brain\u2014multiple paths of regulation","volume":"127","author":"Shah","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bmc.2017.09.011_b0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fj.12-217497","article-title":"A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer\u2019s disease phenotypes in model mice","volume":"27","author":"Shukla","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2017.09.011_b0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.emboj.7600441","article-title":"A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons","volume":"24","author":"Zheng","year":"2005","journal-title":"EMBO J"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808961731194X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808961731194X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:59:12Z","timestamp":1760835552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808961731194X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S096808961731194X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.09.011","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic peptides for CNS indications: Progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}